Overview

Effects of XOMA 052 on Insulin Production in Type 1 Diabetes

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
To assess the effects of treatment with XOMA 052 on beta-cell function and insulin production in subjects with well-controlled Type 1 diabetes. The safety, tolerability, and pharmacokinetics (PK) of XOMA 052 will also be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
University of Zurich
Collaborator:
XOMA (US) LLC